N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide

[email protected]
N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide
Trade Name
Orphan Indication Duchenne muscular dystrophy
USA Market Approval USA
USA Designation Date 2014-11-17 00:00:00
Sponsor Catabasis Pharmaceuticals, Inc.;One Kendall Square, Suite B14202, Suite B14202;Cambridge, Massachusetts, 02139
Related Access Program
PTC Therapeutics – Duchenne Muscular Dystrophy Marathon Pharmaceuticals, LLC. – Duchenne muscular dystrophy PTC Therapeutics International Limited – Duchenne muscular dystrophy